Advancing Hybrid Implant Technologies: Integrating Titanium and Magnesium-Based Innovations

2026-07-22

Aseptic loosening, responsible for about 55.2% of hip arthroplasty revision surgeries globally, is primarily caused by stress shielding. While biomedical titanium (Ti) alloys offer high specific strength, they are bioinert and contribute to stress shielding. Conversely, magnesium (Mg) alloys, with their lower Young’s modulus, reduce stress shielding and offer better biocompatibility, although they suffer from issues of uncontrolled degradation. Therefore, combining Ti and Mg in composites holds promise for improving bone repair by harnessing the benefits of both materials. However, the contact between dissimilar metals (Ti and Mg) in body fluids can cause galvanic corrosion, which accelerates the degradation of Ti-Mg hybrid implants. To address this issue, the HITECH project proposes using a bioactive magnesium oxide (MgO) coating at the Ti-Mg interface. The project aims to advance hybrid implants for hip arthroplasty by achieving four key objectives: (1) Developing a fabrication process that incorporates additive manufacturing, bioactive coatings, acid etching, and capillary-assisted pressure-less infiltration techniques; (2) Controlling galvanic corrosion through surface modification of Ti; (3) Evaluating mechanical behaviors under in vitro corrosion conditions; and (4) Enhancing in vitro biocompatibility by integrating osteoblast-type cells. The project seeks to merge Dr. Dutta’s extensive material knowledge and experience, combined with the biomedical expertise, diverse backgrounds, and broad collaboration networks of the supervisors, supported by the state-of-the-art infrastructure at Helmholtz Zentrum Hereon. This interdisciplinary research spanning metallurgy, advanced coatings, bio-laboratory work, and modeling will broaden Dr. Dutta’s expertise and significantly enhance career opportunities. Helmholtz Zentrum Hereon will benefit from the researcher’s contributions to its research initiatives and industrial applications.

Germany

2026-01-01